The global cancer cachexia market size reached US$ 2.0 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 2.6 Billion by 2028, exhibiting a CAGR of 4.47% during 2022-2028.
Cancer cachexia refers to a multifactorial, host-phagocytic, wasting syndrome that is characterized by systematic inflammation, involuntary loss of lean body mass, negative protein balance, loss of appetite and muscle atrophy. It is caused due to the occurrence of various chronic diseases, including tuberculosis (TB), multiple sclerosis, chronic obstructive pulmonary disease (COPD) and human immunodeficiency virus (HIV). Cancer cachexia can be treated with the utilization of various therapeutics, such as progestogen, corticosteroid, and combination therapy. Amongst these, a progestogen is a synthetic or natural steroid hormone that improves appetite and promotes weight gain, whereas corticosteroid assists in mitigating inflammation and suppressing overactive immune systems.
Cancer cachexia refers to a multifactorial, host-phagocytic, wasting syndrome that is characterized by systematic inflammation, involuntary loss of lean body mass, negative protein balance, loss of appetite and muscle atrophy. It is caused due to the occurrence of various chronic diseases, including tuberculosis (TB), multiple sclerosis, chronic obstructive pulmonary disease (COPD) and human immunodeficiency virus (HIV). Cancer cachexia can be treated with the utilization of various therapeutics, such as progestogen, corticosteroid, and combination therapy. Amongst these, a progestogen is a synthetic or natural steroid hormone that improves appetite and promotes weight gain, whereas corticosteroid assists in mitigating inflammation and suppressing overactive immune systems.
Cancer Cachexia Market Trends:
The increasing prevalence of cancer and cachexia, especially amongst the rising geriatric populations, is facilitating the demand for advanced therapeutic treatment and drugs, which in turn, is primarily driving the market growth. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia. Additionally, the shifting inclination of patients toward combinational therapies for improving lean body mass (LBM) through pharmacological, non-pharmacological therapies and clinical trials is acting as another growth-inducing factor. In line with this, the extensive utilization of several appetite stimulants, such as megestrol acetate, dexamethasone, and methylprednisolone, for improving digestion is also contributing to the market growth. Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth. Apart from this, the numerous favorable initiatives being undertaken by the government bodies of various countries and non-governmental organizations (NGOs) for sensitizing people regarding the causes of cancer cachexia, their symptoms and benefits of using advanced treatments are creating a positive outlook for the market.Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global cancer cachexia market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapeutics, mode of action and distribution channel.Breakup by Therapeutics:
- Progestogens
- Corticosteroids
- Combination Therapy
- Others
Breakup by Mode of Action:
- Appetite Stimulators
- Weight Loss Stabilizers
Breakup by Distribution Channel:
- Hospital Stores
- Retail Pharmacy
- Online Pharmacy
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE & Co. KGaA), Helsinn Healthcare SA, Merck & Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma.Key Questions Answered in This Report:
- How has the global cancer cachexia market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global cancer cachexia market?
- What are the key regional markets?
- What is the breakup of the market based on the therapeutics?
- What is the breakup of the market based on the mode of action?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global cancer cachexia market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Cancer Cachexia Market
6 Market Breakup by Therapeutics
7 Market Breakup by Mode of Action
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- AAVogen Inc.
- Actimed Therapeutics Ltd.
- Aphios Corporation
- Artelo Biosciences Inc.
- AVEO Pharmaceuticals Inc.
- Fresenius Kabi AG (Fresenius SE & Co. KGaA)
- Helsinn Healthcare SA
- Merck & Co. Inc.
- NGM Biopharmaceuticals Inc.
- Pfizer Inc.
- Tetra Bio-Pharma
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 143 |
| Published | March 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 2 Billion |
| Forecasted Market Value ( USD | $ 2.6 Billion |
| Compound Annual Growth Rate | 4.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
Related Reports
Cancer Cachexia - Global Strategic Business Report
- Report
- 255 Pages
- Global
From
From
From
Global Cancer Cachexia Market Report and Forecast 2023-2031
- Report
- 147 Pages
- Global
From
Cancer Cachexia Market - Forecasts from 2024 to 2029
- Report
- 145 Pages
- Global
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The electronic report will be emailed to you. The file formats are PDF and Excel. This product is a market research report. This is a 1-5 user license, allowing up to five users have access to the product. The electronic report will be emailed to you. The file formats are PDF and Excel. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The electronic report will be emailed to you. The file formats are PDF and Excel. 
